Abstract
Although hypofunction of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission is proposed to play an important role in the pathophysiology of schizophrenia, results of the clinical trials of small molecules that enhance the NMDA function are inconsistent. A meta-analysis of all the double-blind, placebo-controlled studies in patients with schizophrenia was performed to examine their efficacy on different symptom domains, the dose-response, the effects of concomitant antipsychotics, and their side effects. About eight hundred subjects from 26 studies were included in current meta-analysis. Overall, the NMDA-enhancing molecules are effective in most schizophrenic symptom domains with the effect size (ES) of total psychopathology of 0.40 (p < 1x10-4). The ES of clinical efficacy of the symptom domains were in the order of depressive (0.40, p=3x10-4), negative (0.38, p < 1x10-4), cognitive (0.28, p=2x10-3), positive symptom (0.26, p=0.0006), and general psychopathology (0.26, p=0.006). Glycine, D-serine, and sarcosine treatments significantly improved multiple symptom domains, whereas D-cycloserine did not improve any symptom domain. Moderator analysis revealed that glycine, D-serine and sarcosine are better than D-cycloserine in improving the overall psychopathology. Patients receiving risperidone or olanzapine, but not clozapine, improved. No significant side effect or safety concern was noted. In addition to testing more lead compounds, long-term trials are required to determine their functional improvement capacity. Other drug targets that may enhance NMDA neurotransmission other than the molecules tested so far need to be explored.
Keywords: pathophysiology, N-methyl-D-aspartate, Schizophrenia, receptor, neurotransmission
Current Pharmaceutical Design
Title: Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis
Volume: 16 Issue: 5
Author(s): Guochuan E. Tsai and Pao-Yen Lin
Affiliation:
Keywords: pathophysiology, N-methyl-D-aspartate, Schizophrenia, receptor, neurotransmission
Abstract: Although hypofunction of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission is proposed to play an important role in the pathophysiology of schizophrenia, results of the clinical trials of small molecules that enhance the NMDA function are inconsistent. A meta-analysis of all the double-blind, placebo-controlled studies in patients with schizophrenia was performed to examine their efficacy on different symptom domains, the dose-response, the effects of concomitant antipsychotics, and their side effects. About eight hundred subjects from 26 studies were included in current meta-analysis. Overall, the NMDA-enhancing molecules are effective in most schizophrenic symptom domains with the effect size (ES) of total psychopathology of 0.40 (p < 1x10-4). The ES of clinical efficacy of the symptom domains were in the order of depressive (0.40, p=3x10-4), negative (0.38, p < 1x10-4), cognitive (0.28, p=2x10-3), positive symptom (0.26, p=0.0006), and general psychopathology (0.26, p=0.006). Glycine, D-serine, and sarcosine treatments significantly improved multiple symptom domains, whereas D-cycloserine did not improve any symptom domain. Moderator analysis revealed that glycine, D-serine and sarcosine are better than D-cycloserine in improving the overall psychopathology. Patients receiving risperidone or olanzapine, but not clozapine, improved. No significant side effect or safety concern was noted. In addition to testing more lead compounds, long-term trials are required to determine their functional improvement capacity. Other drug targets that may enhance NMDA neurotransmission other than the molecules tested so far need to be explored.
Export Options
About this article
Cite this article as:
Tsai E. Guochuan and Lin Pao-Yen, Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis, Current Pharmaceutical Design 2010; 16 (5) . https://dx.doi.org/10.2174/138161210790361452
DOI https://dx.doi.org/10.2174/138161210790361452 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders
Current Pharmaceutical Design Prolyl Oligopeptidase Structure and Dynamics
CNS & Neurological Disorders - Drug Targets Islet Amyloid Polypeptide and Diabetes
Current Protein & Peptide Science Topical Delivery of Drugs for the Effective Treatment of Fungal Infections of Skin
Current Pharmaceutical Design Intra - and Intercellular Calcium Handling in Pulmonary Arterial Hypertension
Medicinal Chemistry Review: Involvement of the Cavum Septi Pellucidi and the Fornix in the Neuropathology of Schizophrenia and Affective Disorders
Current Psychiatry Reviews The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Therapeutic Potential of Peptide Motifs - Part II (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Expectancy and the Treatment of Depression: A Review of Experimental Methodology and Effects on Patient Outcome
Current Psychiatry Reviews Psychological Stress and the Development of Heart Disease
Current Psychiatry Reviews Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets η-Secretase: Reduction of Amyloid Precursor Protein η-Site Cleavage in Alzheimers Disease
Current Alzheimer Research Inflammatory Responses in Brain Ischemia
Current Medicinal Chemistry Chromatin Remodeling, DNA Damage Repair and Aging
Current Genomics Epigenetic Basis of Neuronal and Synaptic Plasticity
Current Topics in Medicinal Chemistry Causes and Effects of Cellular Oxidative Stress as a Result of MDMA Abuse
Current Pharmaceutical Biotechnology The Impact of Alexithymia on Anxiety Disorders: a Review of the Literature
Current Psychiatry Reviews β-amyloid and Oxidative Stress: Perspectives in Drug Development
Current Pharmaceutical Design Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
Current Drug Safety Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry